David Sidransky is an Oncology physician affiliated with Johns Hopkins University. OpenAlex indexes 22 publications with 679 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
720 Rutland Ave
Baltimore, MD 212052109
Telephone
410-502-5153Registry record last updated 11 Sept 2025.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Secura Bio, Inc.Program year202313 payments$312,787openpaymentsdata.cms.gov ↗
- SECURA BIO, INC.Program year202210 payments$207,178openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
14 NIH research awards on record, funded 1997–2026 per NIH RePORTER. The latest:
- DNA evaluation of fragments for early interception (DELFI) of Lung cancer
Johns Hopkins University
FY2026$1,032,472U01CA271896 - Racial differences in Immunogenetic Tumorigenesis of Head and Neck Squamous Cell Carcinoma
Johns Hopkins University
FY2026$411,177R01CA265975 - DNA evaluation of fragments for early interception (DELFI) of Lung cancer
Johns Hopkins University
FY2025$1,043,393U01CA271896
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- TCL-137: Duvelisib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results From the Phase 2 PRIMO Trial
Clinical Lymphoma Myeloma & Leukemia
2025 - POSTER: TCL-137 Duvelisib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results From the Phase 2 PRIMO Trial
Clinical Lymphoma Myeloma & Leukemia
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Roger Blumenthal, MD
Johns Hopkins University
Erin Michos, MD
Johns Hopkins University
Morgan Grams, MD
Johns Hopkins University
Mario Eisenberger, MD
Johns Hopkins University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”